

Todd Kremin

From: Robert Trumpy
Sent: Monday, June 12, 2006 2:54 PM
To: 'mcs@barronpartners.com'
Subject: redraft
Attachments: Barron Letter of Intent 6-11-06 REDLINE.doc

Hank will not be the chairman of Newco – that will be Mary Redino.

Rob Trumpy, CPA
SVP and CFO
BioSafe Medical Technologies, Inc.
100 Field Drive, Suite 240
Lake Forest, IL 60045
Work: 847-234-8111
Fax: 847-234-8222
rtrumpy@ebiosafe.com

4/28/2008

Exhibit 16

LETTER OF INTENT FOR NEWCO, INC. ("COMPANY")

June 1, 2006

Marv Rodino

President

Newco, Inc.

Dear Ms. Rodino,

The following outlines the structure of the stock purchase by Barron Partners LP.

Assumptions:

- 1) \$1.85 million in run-rate seasonal adjusted annualized EBITDA minus \$0.40 million in additional legal and public costs and \$0.18 million recurring capital expenditures from BIOSAFE Medical Technologies, Inc ("BIOSAFE") licensed products to Company
- 2) \$0.0 million in total debt at closing
- 3) Company pays all closing costs and any banking fees at closing out of proceeds
- 4) Board of directors shall be composed of five or seven directors of which a majority shall be independent
- 5) Acquisition of a fully listed shell on either the AMEX, OTC BB, or Pink Sheets
- 6) 6.21 million total fully diluted shares outstanding pre Barron investment
- 7) 10.0 million total fully diluted shares outstanding post Barron investment
- 8) Company and subsidiaries must be fully reporting with SEC as condition of closing and have full audits complete
- 9) Barron will require a due diligence fee which will cover all our expenses of \$85,000.00 out of proceeds at closing
- 10) BIOSAFE will require execution by Company of license agreement for the products licensed to Company
- 11) Each party will pay and be solely responsible for its own expenses, excluding the \$85,000 Barron due diligence fee paid at closing

Security Terms:

- 1) Fixed Price Convertible Preferred Securities
- 2) No Coupon or Dividend attached to the Convertible Preferred Security
- 3) Barron will not have any board seats or control provisions
- 4) Barron can never convert into more than 4.9% of the common stock at any given time.
- 5) Barron will not short the stock or use any market based metrics within its investment.

Total Initial Purchase Price:

\$2.0 million cash

Equities to be purchased: 3.774 million shares at \$0.53 per share

Use of Proceeds:

1) Barron Due Diligence Fee	\$ 85,000
2) Banking Fees and Closing Costs	\$ 145,000
3) Biosafe License fee (\$200,000 per product)	\$1,000,000
4) Company Working Capital	\$ 760,000
Total	\$2,000,000

Warrants:

Warrants to purchase 1.887 million shares of common stock at \$0.80 per share, which would yield additional proceeds to the Company of \$1.50 million upon exercise

Warrants to purchase 1.887 million shares of common stock at \$1.10 per share, which would yield additional proceeds to the Company of \$2.075 million upon exercise

Upon exercise the warrants would yield proceeds to the Company of \$3.576 million at an average price of \$0.95 per share.

Total financing upon exercise of warrants at exercise price plus common stock purchased would yield \$5.576 million at an average price per share of \$0.74.

Exclusivity:

730 Fifth Avenue, 25th Floor, New York, NY 10019 Tel: 212-359-0200 Fax: 646-607-2223

Deleted: MEDICAL
TECHNOLOGIES

Deleted: Henry A. Warner

Deleted: Chairman

Deleted: Medical Technologies

Deleted: r

Deleted: Henry Warner

Formatted: Font: Bold

Upon acceptance of this Letter of Intent, Management of the Company will grant an exclusive due diligence period until July 30, 2006, whereby Barron its agents will be given reasonable access to the Company's facilities, management personnel, customers and its financial and legal records. During this time the Company and its employees, consultants and advisors will not and will cause the Company not to entertain, solicit or respond to any other offers from any other prospective buyers or merger partners, and will not provide any non public information to any other prospective buyers or merger partners. During the term of this letter of intent the Company and Barron agree that Barron will be the exclusive investor, and will utilize a valuation based upon the Barron Intrinsic Value formula. Proceeding with the contemplated investment is based upon satisfactory completion of due diligence by Barron. The Company agrees to indemnify and hold Barron harmless for any losses, costs and expenses including professional fees that Barron may suffer or incur upon breach of this Letter of Intent. This indemnity will survive the expiration or termination of this letter of intent. BioSafe reserves the right to refuse any change to the offer as described above.

Term:

This offer is valid through July 31, 2006. All obligations and rights will expire if a closing has not occurred or definitive agreement has not been signed by July 31, 2006.

Agreed and Acknowledged,

Barron Partners
Andrew Barron Worden

NEWCO, Inc.
By: Marv Rodino, President

Deleted: Biosafe Medical Technologies
Deleted: Henry Warner